What class of drug is lurbinectedin and what does it treat?
Lurbinectedin (brand name Zepzelca) is an alkylating agent that binds DNA and inhibits transcription, primarily approved for metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy.[1] Similar drugs share mechanisms like DNA alkylation, transcription disruption, or target the same cancer types, especially SCLC or other thoracic tumors.
Top drugs with similar mechanisms (DNA-alkylating or transcription inhibitors)
- Trabectedin (Yondelis): Closest analog—marine-derived alkylating agent that also blocks RNA polymerase II and transcription. FDA-approved for soft tissue sarcoma and ovarian cancer; used off-label or in trials for SCLC. Often compared directly to lurbinectedin due to shared origin and action.[1][2]
- Irinotecan (Camptosar): Topoisomerase I inhibitor causing DNA damage. Standard second-line for SCLC, often combined with other agents.
- Topotecan (Hycamtin): Another topoisomerase I inhibitor, FDA-approved specifically for relapsed SCLC—direct competitor in the same niche.[1]
Common alternatives used in SCLC treatment
For relapsed SCLC like lurbinectedin's indication, oncologists often rotate these:
- Amrubicin: Anthracycline topoisomerase inhibitor, approved in Japan for SCLC; in U.S. trials. Strong response rates in platinum-refractory cases.
- Bendamustine: Alkylating agent with purine analog activity, explored in SCLC trials for its DNA cross-linking effects.
- Temozolomide: Oral alkylating agent (methylates DNA), tested in extensive-stage SCLC with modest activity.[2]
How do they compare head-to-head?
| Drug | Mechanism | Key Approvals | SCLC Response Rate (relapsed) | Common Side Effects |
|------|-----------|---------------|-------------------------------|---------------------|
| Lurbinectedin | DNA binding/transcription block | Metastatic SCLC (post-platinum) | ~35% | Neutropenia, fatigue, nausea |
| Trabectedin | DNA binding/transcription block | Sarcoma, ovarian | ~20-30% (SCLC trials) | Myelosuppression, liver toxicity |
| Topotecan | Topoisomerase I inhibition | Relapsed SCLC | ~15-25% | Severe neutropenia, diarrhea |
| Irinotecan | Topoisomerase I inhibition | Colorectal, SCLC (off-label) | ~20-40% (combo) | Diarrhea, myelosuppression |
| Amrubicin | Topoisomerase II inhibition | SCLC (Japan) | ~30-50% | Cardiotoxicity, neutropenia[2] |
Lurbinectedin edges out topotecan in progression-free survival per trials, but trabectedin matches its profile best for mechanism.[1]
Emerging options and biosimilars
No biosimilars for lurbinectedin yet—it's synthetic, not biologic. Pipeline includes:
- Zaltrap (ziv-aflibercept): VEGF trap for SCLC combos.
- Immunotherapies like atezolizumab or lurbinectedin combos, shifting from cytotoxics.
Patents on lurbinectedin extend to 2031 in key markets; check DrugPatentWatch.com for challenges.[3]
[1] FDA.gov - Zepzelca Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] NCCN Guidelines - Small Cell Lung Cancer (2023). https://www.nccn.org/guidelines
[3] DrugPatentWatch.com - Lurbinectedin Patents. https://www.drugpatentwatch.com/p/tradename/ZEPZELCA